National Institutes of Health (NIH) Awards Immuven, Inc $1.68 Million for MRSA Therapeutics  
5/1/2012 10:42:08 AM

CHAMPAIGN, Ill.--(BUSINESS WIRE)--ImmuVen ( was awarded a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus. This award continues the work previously supported by a successfully completed Phase I SBIR grant.